What is the share price of Balaxi Pharmaceuticals Ltd (BALAXI) today?
The share price of BALAXI as on 28th March 2025 is ₹63.92. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Balaxi Pharmaceuticals Ltd (BALAXI) share?
The past returns of Balaxi Pharmaceuticals Ltd (BALAXI) share are- Past 1 week: -8.87%
- Past 1 month: 25.75%
- Past 3 months: -8.84%
- Past 6 months: -40.14%
- Past 1 year: -35.56%
- Past 3 years: -16.04%
- Past 5 years: 350.46%
What are the peers or stocks similar to Balaxi Pharmaceuticals Ltd (BALAXI)?
The peers or stocks similar to Balaxi Pharmaceuticals Ltd (BALAXI) include:What is the market cap of Balaxi Pharmaceuticals Ltd (BALAXI) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Balaxi Pharmaceuticals Ltd (BALAXI) is ₹356.03 Cr as of 28th March 2025.What is the 52 week high and low of Balaxi Pharmaceuticals Ltd (BALAXI) share?
The 52-week high of Balaxi Pharmaceuticals Ltd (BALAXI) is ₹151.45 and the 52-week low is ₹50.42.What is the PE and PB ratio of Balaxi Pharmaceuticals Ltd (BALAXI) stock?
The P/E (price-to-earnings) ratio of Balaxi Pharmaceuticals Ltd (BALAXI) is -148.35. The P/B (price-to-book) ratio is 1.77.Which sector does Balaxi Pharmaceuticals Ltd (BALAXI) belong to?
Balaxi Pharmaceuticals Ltd (BALAXI) belongs to the Health Care sector & Health Care Equipment & Supplies sub-sector.How to buy Balaxi Pharmaceuticals Ltd (BALAXI) shares?
You can directly buy Balaxi Pharmaceuticals Ltd (BALAXI) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Balaxi Pharmaceuticals Ltd
BALAXI Share Price
63.921.30% (-0.84)
BALAXI Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
BALAXI Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 13.01 | 1.77 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.27 | 6.30 | 0.54% |
BALAXI Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BALAXI Company Profile
The company is engaged in wholesale trading of pharmaceuticals products, food products and builders’ hardware products. The Company offers a range of food and biscuit products under the brand name YAP.
Investor Presentation
View olderBALAXI Similar Stocks (Peers)
Compare with peersPE Ratio
66.62
1Y Return
19.35%
Buy Reco %
0.00
POLYMED
PE Ratio
86.41
1Y Return
41.28%
Buy Reco %
80.00
LAXMIDENTL
PE Ratio
95.01
1Y Return
19.14%
Buy Reco %
100.00
TARSONS
PE Ratio
38.72
1Y Return
23.31%
Buy Reco %
80.00
BOROSCI
PE Ratio
45.63
1Y Return
22.02%
Buy Reco %
—
BALAXI Forecasts
Price
Revenue
Earnings
BALAXI Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeBALAXI Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeBALAXI Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeBALAXI
Income
Balance Sheet
Cash Flow
Annual Normal View
BALAXI Income Statement
Annual Normal View
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 14.49 | 46.22 | 233.56 | 284.36 | 339.07 | 241.92 | 273.41 | |||||||
Raw Materials | 0.00 | 32.83 | 172.15 | 195.60 | 202.42 | 128.68 | 238.00 | |||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.35 | 0.28 | 0.04 | ||||||||
| Employee Cost | 0.90 | 2.10 | 8.47 | 12.47 | 28.95 | 28.04 | ||||||||
| Selling & Administrative Expenses | 0.59 | 1.75 | 4.74 | 17.56 | 42.29 | 36.02 | ||||||||
| Operating & Other expenses | 10.55 | 0.70 | 3.30 | 2.59 | 5.08 | 42.27 | ||||||||
EBITDA | 2.45 | 8.84 | 44.90 | 55.79 | 60.05 | 6.87 | 35.41 | |||||||
| Depreciation/Amortization | 0.00 | 0.01 | 0.30 | 0.51 | 1.75 | 2.10 | 2.10 | |||||||
| PBIT | 2.45 | 8.83 | 44.60 | 55.28 | 58.30 | 4.77 | 33.31 | |||||||
| Interest & Other Items | 0.00 | 0.05 | 0.28 | 0.76 | 1.38 | 2.77 | 2.81 | |||||||
| PBT | 2.45 | 8.78 | 44.32 | 54.52 | 56.92 | 2.00 | 30.50 | |||||||
| Taxes & Other Items | 0.47 | 2.69 | 6.19 | 6.86 | 10.96 | 4.40 | 3.13 | |||||||
| Net Income | 1.98 | 6.09 | 38.13 | 47.66 | 45.96 | -2.40 | 27.37 | |||||||
| EPS | 1.30 | 1.87 | 7.63 | 9.53 | 9.11 | -0.46 | 5.02 | |||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | |||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
BALAXI Company Updates
FY 2022
Investor Presentation
Jun 24PDF
Feb 15PDF
FY 2023
Investor Presentation
May 29PDF
Feb 1PDF
Nov 5PDF
+2 more
FY 2024
Investor Presentation
Aug 3PDF
FY 2025
Investor Presentation
Feb 13PDF
Nov 13PDF
BALAXI Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHealth Care Equipment & Supplies
Compare valuation on Screener
Health CareHealth Care Equipment & Supplies
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Balaxi Pharmaceuticals Ltd | -148.35 | 1.77 | — |
| Inventurus Knowledge Solutions Ltd | 66.62 | 21.32 | 0.69% |
| Poly Medicure Ltd | 86.41 | 15.18 | 0.13% |
| Laxmi Dental Ltd | 95.01 | 52.85 | — |
BALAXI Stock Price Comparison
Compare BALAXI with any stock or ETFCompare BALAXI with any stock or ETF
BALAXI
BALAXI Shareholdings
BALAXI Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BALAXI Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BALAXI Shareholding Pattern
BALAXI Shareholding History
Foreign Institutions
smallcases containing BALAXI stock
Looks like this stock is not in any smallcase yet.
BALAXI Events
BALAXI Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BALAXI Upcoming Dividends
No upcoming dividends are available
BALAXI Past Dividends
Cash Dividend
Ex DateEx DateJul 1, 2022
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jul 1, 2022
BALAXI Stock News & Opinions
Articles & Videos
Earnings
Balaxi Pharmaceuticals consolidated net profit declines 60.56% in the December 2024 quarter
Net profit of Balaxi Pharmaceuticals declined 60.56% to Rs 5.36 crore in the quarter ended December 2024 as against Rs 13.59 crore during the previous quarter ended December 2023. Sales rose 20.56% to Rs 73.29 crore in the quarter ended December 2024 as against Rs 60.79 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales73.2960.79 21 OPM %5.4422.47 - PBDT6.5513.11 -50 PBT6.0712.63 -52 NP5.3613.59 -61 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals to convene board meeting
Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Balaxi Pharmaceuticals consolidated net profit declines 68.19% in the September 2024 quarter
Net profit of Balaxi Pharmaceuticals declined 68.19% to Rs 4.59 crore in the quarter ended September 2024 as against Rs 14.43 crore during the previous quarter ended September 2023. Sales rose 41.41% to Rs 77.38 crore in the quarter ended September 2024 as against Rs 54.72 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales77.3854.72 41 OPM %13.6919.66 - PBDT6.0310.67 -43 PBT5.5610.01 -44 NP4.5914.43 -68 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals announces board meeting date
Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 November 2024Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Balaxi Pharmaceuticals reports consolidated net profit of Rs 6.48 crore in the June 2024 quarter
Net profit of Balaxi Pharmaceuticals reported to Rs 6.48 crore in the quarter ended June 2024 as against net loss of Rs 41.34 crore during the previous quarter ended June 2023. Sales declined 0.52% to Rs 65.62 crore in the quarter ended June 2024 as against Rs 65.96 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales65.6265.96 -1 OPM %15.3813.40 - PBDT7.877.54 4 PBT7.377.26 2 NP6.48-41.34 LP Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals to conduct AGM
Balaxi Pharmaceuticals announced that the 81st Annual General Meeting(AGM) of the company will be held on 23 August 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals to convene board meeting
Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 75.6%, vs industry avg of 17.71%
Over the last 5 years, market share increased from 1.21% to 4.44%